GMAB

Company Announcement Net sales of DARZALEX ® in the third quarter of 2026 totaled USD 4,239 million Genmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc.) COPENHAGEN, Denmark; October 13, 2026 – Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX (daratumumab), including sales of the subcutaneous (SC) product ( daratumumab and hyaluronidase-fihj , sold under the tradename DARZALEX FASPRO ® in the U.S. ) , as reported by J&J were USD 4,239 million in the third quarter of 2026. Net trade sales were USD 2,528 million in the U.S. and USD 1,711 million in the rest of the world.

Genmab delivered strong topline results for Epkinly in frontline DLBCL, showing a 51% reduction in risk of progression or death. Epkinly's efficacy notably exceeds Roche's Polivy in similar settings, positioning GMAB as a potential market leader among T-cell engagers. Frontline DLBCL represents the key growth driver for Epkinly, and I see upside to the company's $3 billion+ peak sales guidance based on better-than-expected treatment effect.

ABBV's epcoritamab plus R-CHOP cut progression or death risk by 51% in frontline DLBCL, meeting the phase III study's PFS goal.

Genmab (GMAB) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

The Danish company said the Epkinly drug helped extend the time patients with a common type of lymphoma lived.

EPCORE DLBCL-2 is the first Phase 3 study of a bispecific antibody combination therapy to demonstrate statistically significant and clinically meaningful improvement in progression-free survival (PFS) in frontline diagnosed diffuse large B-cell lymphoma (DLBCL) patients Based on the topline results, Genmab and AbbVie will engage global regulatory authorities NORTH CHICAGO, Ill. and COPENHAGEN, Denmark, Oct. 5, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Genmab A/S  (Nasdaq: GMAB) today announced positive topline results from the Phase 3 EPCORE DLBCL-2 trial evaluating fixed treatment duration epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, in combination with standard of care rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone (R-CHOP), compared to R-CHOP alone, in newly diagnosed patients with diffuse large B-cell lymphoma (DLBCL) with an International Prognostic Index (IPI) score of 2 to 5.

Company Announcement COPENHAGEN, Denmark and NORTH CHICAGO, Ill.; October 5, 2026 EPCORE DLBCL-2 is the first Phase 3 study of a bispecific antibody combination therapy to demonstrate statistically significant and clinically meaningful improvement in progression-free survival (PFS) in frontline diagnosed diffuse large B-cell lymphoma (DLBCL) patients Based on the topline results, Genmab and AbbVie will engage global regulatory authorities Genmab A/S (Nasdaq: GMAB) and AbbVie (NYSE: ABBV) announced today positive topline results from the Phase 3 EPCORE DLBCL-2 trial evaluating fixed treatment duration epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, in combination with standard of care rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone (R-CHOP), compared to R-CHOP alone, in newly diagnosed patients with diffuse large B-cell lymphoma (DLBCL) with an International Prognostic Index (IPI) score of 2 to 5.

Company Announcement COPENHAGEN, Denmark; September 24, 2026 – Genmab A/S (Nasdaq: GMAB) announced today that the Board of Directors decided to grant 13,794 restricted stock units and 13,331 warrants to employees of the Company and the Company's subsidiaries. Each restricted stock unit is awarded cost-free and provides the owner with a conditional right to receive one share in Genmab A/S of nominally DKK 1.

Genmab A/S (GMAB) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Genmab A/S (GMAB) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript